Overview Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD Status: Completed Trial end date: 2019-02-14 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD Phase: Phase 3 Details Lead Sponsor: Supernus Pharmaceuticals, Inc.